15-Minute iron shot could beat anemia fast
NCT ID NCT01374919
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested a single 15-minute infusion of ferumoxytol, a type of intravenous iron, in 60 people with iron deficiency anemia who couldn't take oral iron. The goal was to see if this quick dose safely raises hemoglobin levels. Researchers checked for side effects right after the infusion and during follow-up calls and visits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ferumoxytol (intravenous iron)
- What this could lead to
- If successful, this could offer a quicker, more convenient way to treat iron deficiency anemia with a single 15-minute infusion.
- What could go wrong
- This is a small, completed trial with only 60 participants, so results may not apply to everyone. There is a risk of allergic reactions to ferumoxytol.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Start date
-
Jun 2011
- Finished
-
Mar 2012
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Iron deficiency anemia intolerant of or failure to respond to oral iron or condition where oral iron is known to be ineffective or harmful. * Subject must be able to be contacted at 24-48 hours after dose and come for followup at four weeks. * Subject must be capable of understanding informed consent * No other form of iron may be taken within four weeks of consent or for four weeks after treatment Exclusion Criteria: * History of hypersensitivity to ferumoxytol. * Imminent dialysis. * Anemia due to other etiology. * Parenteral iron within 4 weeks of consent. * Pregnancy. * Erythropoiesis stimulating agent within 30 days of consent. * Other illness that would interfere with participation or understanding of trial. * Major surgery planned within four weeks of consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Iron deficiency anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Auerbach Hematology and Oncology
Baltimore, Maryland, 21237, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can starting iron sooner protect preterm babies on donor milk?
- Can treating anemia before pregnancy stop it later?
- Can a new iron injection match the standard treatment?
- One infusion before surgery: could it cut transfusions?
- Iron and folic acid: a simple pill that could ease anemia and heart symptoms?
- A simple nutrient may shield Babies' brains from iron deficiency